Skymab Biotherapeutics
PrivateLast Round
Grant
Jun 2, 2026
Total Funding Raised
$690,000
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Skymab Biotherapeutics is a drug discovery company that designs, engineers, and develops antibody-drug conjugates (ADCs) targeting G-protein-coupled receptors (GPCRs) for applications in oncology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Skymab Biotherapeutics Comparables
Compare Skymab Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Daiichi Sankyo | 74% | |
| AstraZeneca | 72% | |
| Confo Therapeutics | 69% | |
Skymab Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 2, 2026 | ||||
| Grant | Feb 16, 2024 | ||||
| Grant | Jul 16, 2020 |
Skymab Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Pfizer | Grant |
| Paris-Saclay Cancer Cluster | Grant |
| Bpifrance | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 2, 2026
Received grant funding from Paris-Saclay Cancer Cluster.
- Feb 16, 2024
Received grant funding from Pfizer.
Skymab Biotherapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Skymab Biotherapeutics's valuation, stock price, and market status.